Trials / Unknown
UnknownNCT04484025
SPI-1005 Treatment in Moderate COVID-19 Patients
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Sound Pharmaceuticals, Incorporated · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ebselen | Glutathione peroxidase mimetic |
| DRUG | Placebo | Matching placebo containing excipients |
Timeline
- Start date
- 2021-10-12
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2020-07-23
- Last updated
- 2023-10-03
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04484025. Inclusion in this directory is not an endorsement.